Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex immunomodulatory pilot study after total hip replacement
NL-OMON51373Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoarthritis (OA) and hip osteoarthritis comparing Sugammadex with Placebo (2 arms). Primary endpoint: Postoperative innate immune function. Started Mar 2023; status: completed.
02
Drugs
Sugammadex
03
Conditions
osteoarthritis (OA)hip osteoarthritis
Beyond the preview
Go deeper on NL-OMON51373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51373.